Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial

BACKGROUND: Tolvaptan (TLV) is reported to improve diuretic effects in patients with chronic kidney disease (CKD) when furosemide (FUR) is not sufficiently effective. However, it is not clear whether TLV addition is effective for advanced CKD patients with heart failure. METHODS: An open-label, para...

Descripción completa

Detalles Bibliográficos
Autores principales: Komiya, Shiro, Katsumata, Mari, Ozawa, Moe, Haze, Tatsuya, Kawano, Rina, Ohki, Yuki, Suzuki, Shota, Kobayashi, Yusuke, Fujiwara, Akira, Saka, Sanae, Tamura, Kouichi, Hirawa, Nobuhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385808/
https://www.ncbi.nlm.nih.gov/pubmed/35471469
http://dx.doi.org/10.1007/s10157-022-02224-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385808/
https://www.ncbi.nlm.nih.gov/pubmed/35471469
http://dx.doi.org/10.1007/s10157-022-02224-x

Ejemplares similares